Power3's Invited Review on Biomarkers and Test for ALS, Parkinson's, and Alzheimer's is Published by Expert Reviews of Proteomics.

HOUSTON -- Power3 Medical Products, Inc. (Pink Sheets:PWRM), a leader in the development of blood serum-based diagnostic tests for early-detection of cancer and neurodegenerative diseases, announced today the publication of an invited review co-authored by its chief scientific officer and other key members of its senior technical management team.

The invited review, "2D Gel Blood Serum Biomarkers Reveal Differential Clinical Proteomics of the Neurodegenerative Diseases" is in the current issue of "Expert Reviews of Proteomics," and outlines the scientific groundwork for Power3's NuroPro(R) suite of blood serum tests for neurodegenerative diseases, including ALS, Parkinson's and Alzheimer's.

Power3 currently has 19 provisional and utility patent applications pending with the U.S. Patent and Trademark Office involving biomarker discovery and test designs for breast, stomach and esophageal cancer, neurodegenerative disease, and drug targets for resistance to chemotherapy.

Steven B. Rash, chairman and CEO of Power3, said he was "very proud that this important review was invited and published.

"To have our company and our innovative work recognized by scientific and healthcare industry peers is very rewarding and satisfying," he said.

The 18-page article was written by Dr. Ira Goldknopf, Power3's chief scientific officer, Dr. Essam A. Sheta, its director of biochemistry, and Dr. Stanley H. Appel. A member of Power3's Scientific Advisory Board, Dr. Appel is former chairman of the Department of Neurology, past director of the Vicki Appel MDA/ALS Clinic, past-director of the Alzheimer's Disease Research Center at Baylor College of Medicine, past director of the Jerry Lewis Neuromuscular Research Center in Houston and director of the Methodist Neurological Institute in Houston.

Monitoring Multiple Blood Serum Protein Biomarkers

Dr. Goldknopf said the review, which was invited by Expert Reviews of Proteomics, "shows how Power3's tests obtained superior performance by monitoring multiple blood serum protein biomarkers and multivariate biostatistics.

"Power3 was able to define the disease mechanisms for ALS and Parkinson's that can be measured by the blood tests," he said. "The review places our patent-pending technology and methods within the context of overall research as having the only blood protein biomarkers and test for neurodegenerative diseases. We believe the leadership of Power3 Medical in clinical proteomics for differential diagnosis of neurodegenerative diseases is clearly delineated and demonstrated within this review.

Information and reprints are available by contacting [e-mail].

Presentations Set, More Findings to be Published

Power3 is also scheduled to deliver presentations at major scientific conferences this spring and will soon have more of its scientific findings published.

"Blood Serum Biomarkers for Differential Diagnosis of Parkinson's Disease" and "Biomarkers for Diagnosis and Targeting of Resistance and Sensitivity to Imatinib Mesylate in Chronic Myelogenous Leukemia" will be delivered at Experimental Biology 2006 in San Francisco in early April, and "Convergence of Proteome-Diagnostics and Pharmaco-Proteomics toward Personalized Medicine -- Examples from Breast Cancer and Leukemia" will be given at the OncoProteomics World Congress in San Francisco in late April.

In addition, "C3c and Related Protein Biomarkers in Amyotrophic Lateral Sclerosis and Parkinson's Disease," written by Drs. Goldknopf, Sheta and Appel, along with Jennifer Bryson, Brian Folsom, Chris Wilson, Jeff Duty, and Albert A. Yen, has been accepted for publication and is expected to appear in the March or April issue of "Biochemical and Biophysical Research Communications." The article is the result of a collaboration between Power3 Medical Products and the Methodist Neurological Institute of Houston.

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (Pink Sheets:PWRM) is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.